The United States has reinstated India on its notorious Priority Watch List in the 2026 Special 301 Report, citing unresolved intellectual property enforcement failures. Issued by the Office of the US Trade Representative (USTR), the document critiques India’s patent system delays, weak protections, and rampant counterfeiting.
Joining India are heavyweights like China and Russia, underscoring global IP hotspots. The report praises incremental steps, including more patent office staff and public education drives, but laments inconsistent advancement.
Patent bottlenecks—fueled by endless oppositions and red tape—remain a flashpoint. Restrictions on patenting certain innovations, notably in drugs, stifle R&D investment. Agrochemicals and pharmaceuticals suffer from inadequate test data security, eroding trust among foreign firms.
On enforcement, the verdict is damning: ‘India’s overall IP enforcement remains inadequate.’ Piracy thrives online and offline, fake goods flood markets, and official penalties lack bite due to poor inter-agency sync.
Trade secrets get no statutory shield, complicating proprietary tech safeguards. Yet, optimism flickers with recent rule tweaks to expedite patents. USTR commits to dialogue via trade forums.
Jamieson Greer, USTR head, affirmed: ‘Combating unfair trade is paramount.’ Rick Switzer stressed IP’s role for creators: ‘Strong enforcement is vital for American brands.’
As an annual barometer, the Special 301 Report triggers intense monitoring and negotiations. For India-US ties, it spotlights enduring frictions in high-stakes industries like biotech and software, potentially reshaping future pacts.
